Details

Autor(en) / Beteiligte

• Togashi, Kyo
• Hatakeyama, Shingo
• Kojima, Yuta
• Momota, Masaki
• Narita, Takuma
• Iwamura, Hiromichi
• Hamano, Itsuto
• Hamaya, Tomoko
• Fujita, Naoki
• Okamoto, Teppei
• Yoneyama, Tohru
• Yamamoto, Hayato
• Yoneyama, Takahiro
• Hashimoto, Yasuhiro
• Ohyama, Chikara

Titel

The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study)

Ist Teil von

• Urologic oncology, 2021-03, Vol.39 (3), p.192.e7-192.e14

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• •There is not enough evidence available for the association of frailty with health-related quality of life (HRQOL) and lower urinary symptoms (LUTS) following robot-assisted radical prostatectomy (RARP) in patients with prostate cancer (CaP).•We longitudinally evaluated geriatric 8 (G8), HRQOL, and LUTS for 12 months in 118 patients with RARP from February 2017 to April 2020.•Patients were divided into frail (G8 ≤14) and nonfrail (G8 >14) groups.•We found that frailty was not significantly associated with HRQOL and LUTS deterioration in patients with localized CaP. We aimed to evaluate the effect of frailty on health-related quality-of-life (HRQOL) and lower urinary symptoms (LUTS) following robot-assisted radical prostatectomy (RARP) in patients with prostate cancer (CaP). We longitudinally evaluated geriatric 8 (G8), HRQOL, and LUTS for 12 months in 118 patients with RARP from January 2017 to April 2020. Patients were divided into frail (G8 ≤14) and nonfrail (G8 >14) groups. We compared the effect of frailty on HRQOL and LUTS between the frail and nonfrail groups before and 12 months after RARP. The median age of patients was 68 years. The number of patients in the frail and nonfrail groups were 41 and 77, respectively. No significant difference in patients’ background was observed between the groups, except for the presence of cardiovascular disease (22% vs. 7.8%, P = 0.041). There was no significant difference in HRQOLs and LUTS between the groups at baseline. Similarly, HRQOLs, LUTS, and pad-free continence rates were not significantly different between the groups at 12 months after RARP. In the nonfrail group, LUTS at 12 months following RARP significantly improved compared to those at the baseline, but it did not significantly improve in the frail group. Multivariable logistic regression analysis demonstrated that frailty was not significantly associated with LUTS worsening. Frailty was not significantly associated with the worsening of HRQOL, LUTS, and pad-free continence rates in patients treated with RARP.